Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.

ABSTRACT: Despite substantial developments in conventional treatments such as surgery, chemotherapy, radiotherapy, endocrine therapy, and molecular-targeted therapy, breast cancer remains the leading cause of cancer mortality in women. Currently, chimeric antigen receptor (CAR)-redirected immune cell therapy has emerged as an innovative immunotherapeutic approach to ameliorate survival rates of breast cancer patients by eliciting cytotoxic activity against cognate tumour-associated antigens expressing tumour cells. As a crucial component of adaptive immunity, T cells and NK cells, as the central innate immune cells, are two types of pivotal candidates for CAR engineering in treating solid malignancies. However, the biological distinctions between NK cells- and T cells lead to differences in cancer i

SUBMITTER: Nikoo M 

PROVIDER: S-EPMC9344815 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature